Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Ruzsa, A Sen, M Evans, M Lee, Lip W Hideghety, K Rottey, S Klimak, P Holeckova, P Fayette, J Csoszi, T
Ruzsa, A
Sen, M
Evans, M
Lee, Lip W
Hideghety, K
Rottey, S
Klimak, P
Holeckova, P
Fayette, J
Csoszi, T
Citations
Altmetric:
Abstract
To determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Description
Date
2014-12
Publisher
Collections
Keywords
Type
Article
Citation
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). 2014, 32 (6):1278-84 Invest New Drugs